Back to search

Article

TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer

2019-02-25

Abstract excerpt

In treating patients with castration resistant prostate cancer (CRPC), enzalutamide, the second-generation androgen receptor (AR) antagonist, is an accepted standard of care. However, clinical benefits are limited to a median time of 4.8 months because resistance inevitably emerges. To determine the mechanism of treatment resistance, we carried out a RNA sequence analysis and found increased expression levels of n...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ff20d368-1927-5b04-931e-600e8eb62af7
DOI
10.1101/560821
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancerDOI 10.1101/560821
Identification of genes required for enzalutamide resistance in castration-resistant prostate cancer cells <i>in vitro</i>Semantic proximity
Non-drug efflux function of ABCC5 promotes enzalutamide resistance in castration-resistant prostate cancer via upregulation of P65/AR-V7Semantic proximity
Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).Semantic proximity
Non-coding RNAs in enzalutamide resistance of castration-resistant prostate cancerSemantic proximity
ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.Semantic proximity
Targeting SOX4/PCK2 signaling suppresses neuroendocrine trans-differentiation of castration-resistant prostate cancerSemantic proximity
Notch as a Driver of Lineage Plasticity and Therapeutic Target in Enzalutamide-Resistant Prostate CancerSemantic proximity
Molecular and Functional Links between Neurodevelopmental Processes and Treatment-Induced Neuroendocrine Plasticity in Prostate Cancer ProgressionSemantic proximity
Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancerSemantic proximity
PEG10 is associated with treatment-induced neuroendocrine prostate cancerSemantic proximity
A novel REST-regulated lncRNA PCAT-NE1 induces neuroendocrine differentiation in castration-resistant prostate cancerSemantic proximity
Overexpression of RACGAP1 by E2F1 Promotes Neuroendocrine Differentiation of Prostate Cancer by Stabilizing EZH2 ExpressionSemantic proximity
Select a neighboring publication to make it the new centre.